Brain

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as…

2 years ago

Algernon Pharmaceuticals Announces Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 11, 2024…

2 years ago

Hyperfine, Inc. to Announce Second Quarter 2024 Financial Results on August 8, 2024

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared…

2 years ago

Hyperfine, Inc. to Announce Second Quarter 2024 Financial Results on August 8, 2024

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared…

2 years ago

Cumulus Neuroscience to Join Bio-Hermes 2 Study with Funding from the Innovate UK Small Business Research Initiative (SBRI) Dementia Mission Project

Funded by a nearly £1.2M (~$1.5M USD) award, this research will enable ongoing validation of AccelADx™, a breakthrough screening test for…

2 years ago

Aires Tech Partners with Canada Basketball as Official EMF Protection Technology Partner

TORONTO, July 11, 2024 /PRNewswire/ -- In a world where humans and high-volume digital connections are increasingly intertwined, consumers are…

2 years ago

Masimo Exposes Politan’s Governance Hypocrisy

Highlights Quentin Koffey’s Actions That Have Flown in the Face of Good GovernanceIRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”)…

2 years ago

Masimo Exposes Politan’s Governance Hypocrisy

Highlights Quentin Koffey’s Actions That Have Flown in the Face of Good GovernanceIRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”)…

2 years ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data…

2 years ago

Pan Cancer T secures €4.25 Million in Seed Extension Round to advance next-generation T cell therapies

ROTTERDAM, the Netherlands, July 11, 2024 (GLOBE NEWSWIRE) -- Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T…

2 years ago